QQQ3.51%

Trending

RKLB17.22%

home Symbol BIAFnews

BIAFBioAffinity Technologies Inc

$1.63

$0.11

(7.24%)

Today

Closed $1.63

$0.0178

(1.09%)

After Hours

Updated: 07:58 PM EDT

Reported EarningsMay 8

Mkt Cap$6.89M

Vol133,975.00

Fundamentals

Mkt Cap

$6.89M

Volume

52W High

$13.80

52W Low

$0.693

PE Ratio

-0.14

Avg. Volume

211,932.48

EPS (Annual)

-$8.66

Rev/Employee

$108,104.54

Earnings

May 08

Info

News

all

press releases

Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced the Society for Advanced Bronchoscopy (SAB) will host a webinar on CyPath Lungs expanding role in pulmonary, oncology and surgical...

Business Wire

More News

bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath Lung Technology

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath Lung, the Companys commercially available test for early-stage lung cancer, today announced it has received notification of allowance from the Mexican Institute of...

Business Wire

BIAF Stock Slips Post Q1 Earnings Despite Strength in CyPath Lung

bioAffinity posts softer first-quarter 2026 results after exiting lower-margin pathology services, though CyPath Lung adoption and clinical-trial progress gain traction.

Zacks

bioAffinity Technologies Reports Record Monthly CyPath Lung Unit Sales and Significant Year-Over-Year Growth in April 2026

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that unit sales for its CyPath Lung...

Business Wire

bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath Lung

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases...

Business Wire

bioAffinity Technologies Launches New Study To Expand Use of CyPath Lung Technology for Asthma and COPD Diagnosis and Treatment

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced a pilot study with Brooke Army...

Business Wire

bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?

BIAF is sharpening its focus on CyPath Lung, streamlining unprofitable services and pushing validation studies as it expands its lung-disease pipeline.

Zacks

New Case Study: bioAffinity Technologies CyPath Lung Diagnostic Supports Physicians Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today released a new clinical case study...

Business Wire

bioAffinity Technologies CyPath Lung to Be Featured at Cleveland Clinic Annual Advances in Early Lung Cancer Detection Symposium April 16

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, announces that its CyPath Lung test will be featured at...

Business Wire

BIAF Stock Gains As CyPath Sales Surge 146% In Q1

The test is capable of identifying lung cancer at Stage 1A, enhancing chances for effective treatment.

Stocktwits

...

Advertisement|Remove ads.